Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
54% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MYL: 0.03 )
MYL' s 10-Year Cash to Debt Range
Min: 0.03   Max: 38.64
Current: 0.03

0.03
38.64
Equity to Asset 0.21
MYL's Equity to Asset is ranked lower than
51% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. MYL: 0.21 )
MYL' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.9
Current: 0.21

0.19
0.9
Interest Coverage 4.06
MYL's Interest Coverage is ranked higher than
51% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. MYL: 4.06 )
MYL' s 10-Year Interest Coverage Range
Min: 0.83   Max: 9.19
Current: 4.06

0.83
9.19
F-Score: 6
Z-Score: 2.30
M-Score: -2.41
WACC vs ROIC
7.02%
11.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.52
MYL's Operating margin (%) is ranked higher than
88% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. MYL: 17.52 )
MYL' s 10-Year Operating margin (%) Range
Min: 2.31   Max: 36
Current: 17.52

2.31
36
Net-margin (%) 12.04
MYL's Net-margin (%) is ranked higher than
84% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. MYL: 12.04 )
MYL' s 10-Year Net-margin (%) Range
Min: -3.53   Max: 30.52
Current: 12.04

-3.53
30.52
ROE (%) 28.88
MYL's ROE (%) is ranked higher than
97% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. MYL: 28.88 )
MYL' s 10-Year ROE (%) Range
Min: -8.33   Max: 29.99
Current: 28.88

-8.33
29.99
ROA (%) 6.01
MYL's ROA (%) is ranked higher than
82% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. MYL: 6.01 )
MYL' s 10-Year ROA (%) Range
Min: -2.47   Max: 18.43
Current: 6.01

-2.47
18.43
ROC (Joel Greenblatt) (%) 31.12
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. MYL: 31.12 )
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.11   Max: 92.62
Current: 31.12

4.11
92.62
Revenue Growth (3Y)(%) 11.60
MYL's Revenue Growth (3Y)(%) is ranked higher than
82% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. MYL: 11.60 )
MYL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.1   Max: 54.5
Current: 11.6

-6.1
54.5
EBITDA Growth (3Y)(%) 11.30
MYL's EBITDA Growth (3Y)(%) is ranked higher than
80% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. MYL: 11.30 )
MYL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20   Max: 107
Current: 11.3

-20
107
EPS Growth (3Y)(%) 24.20
MYL's EPS Growth (3Y)(%) is ranked higher than
89% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. MYL: 24.20 )
MYL' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.8   Max: 110.4
Current: 24.2

-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MYL Guru Trades in Q1 2014

Jim Simons 1,401,474 sh (New)
Jean-Marie Eveillard 675,428 sh (New)
Louis Moore Bacon 134,160 sh (New)
Paul Tudor Jones 432,717 sh (New)
Andreas Halvorsen 1,776,108 sh (New)
Steven Cohen 553,164 sh (+6.49%)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Mario Gabelli 13,000 sh (unchged)
Joel Greenblatt Sold Out
David Dreman Sold Out
John Paulson 12,130,700 sh (-0.07%)
Scott Black 274,571 sh (-10.63%)
John Hussman 50,000 sh (-75.00%)
» More
Q2 2014

MYL Guru Trades in Q2 2014

Pioneer Investments 226,453 sh (New)
Jean-Marie Eveillard 1,241,991 sh (+83.88%)
Mario Gabelli 13,800 sh (+6.15%)
Vanguard Health Care Fund 4,775,700 sh (unchged)
John Paulson 12,130,700 sh (unchged)
John Hussman 50,000 sh (unchged)
Steven Cohen 83,700 sh (unchged)
Andreas Halvorsen Sold Out
Louis Moore Bacon 100,000 sh (-25.46%)
Scott Black 201,925 sh (-26.46%)
Jim Simons 652,200 sh (-53.46%)
Paul Tudor Jones 4,200 sh (-99.03%)
» More
Q3 2014

MYL Guru Trades in Q3 2014

Ray Dalio 57,106 sh (New)
Paul Tudor Jones 20,015 sh (+376.55%)
Louis Moore Bacon 435,000 sh (+335.00%)
Vanguard Health Care Fund 15,444,880 sh (+223.41%)
John Paulson 12,494,700 sh (+3.00%)
John Hussman 50,000 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
Pioneer Investments 282,805 sh (unchged)
Steven Cohen Sold Out
Scott Black 199,406 sh (-1.25%)
Mario Gabelli 10,000 sh (-27.54%)
Jim Simons 465,200 sh (-28.67%)
Jean-Marie Eveillard 809,603 sh (-34.81%)
» More
Q4 2014

MYL Guru Trades in Q4 2014

Joel Greenblatt 673,287 sh (New)
Paul Tudor Jones 254,152 sh (+1169.81%)
Pioneer Investments 691,198 sh (+144.41%)
John Paulson 14,948,400 sh (+19.64%)
Jean-Marie Eveillard 841,779 sh (+3.97%)
Louis Moore Bacon 200,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Mario Gabelli 10,000 sh (unchged)
Jim Simons Sold Out
Vanguard Health Care Fund 15,037,080 sh (-2.64%)
Ray Dalio 52,706 sh (-7.70%)
Scott Black 181,796 sh (-8.83%)
Louis Moore Bacon 36,196 sh (-91.68%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Mylan NV

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Vanguard Health Care Fund Comments on Mylan NV
We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy. Read more...
Scott Black’s Top First Quarter Holdings
Scott Black is the chairman, president, chief investment officer and founder of Boston-based Delphi Management, and is often featured in Barron’s. Delphi Management’s investment philosophy states that they “only invest in companies that meet our internally developed set of rigorous quantitative criteria.” The fund also only invests in equity securities of US-listed companies, and takes only long positions. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.30
MYL's P/E(ttm) is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. MYL: 26.30 )
MYL' s 10-Year P/E(ttm) Range
Min: 7.05   Max: 112.56
Current: 26.3

7.05
112.56
Forward P/E 13.16
MYL's Forward P/E is ranked higher than
93% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. MYL: 13.16 )
N/A
PE(NRI) 26.30
MYL's PE(NRI) is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. MYL: 26.30 )
MYL' s 10-Year PE(NRI) Range
Min: 7.05   Max: 200.11
Current: 26.3

7.05
200.11
P/B 7.08
MYL's P/B is ranked higher than
54% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. MYL: 7.08 )
MYL' s 10-Year P/B Range
Min: 0.64   Max: 7.25
Current: 7.08

0.64
7.25
P/S 3.18
MYL's P/S is ranked higher than
72% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. MYL: 3.18 )
MYL' s 10-Year P/S Range
Min: 0.41   Max: 4.61
Current: 3.18

0.41
4.61
PFCF 93.38
MYL's PFCF is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. MYL: 93.38 )
MYL' s 10-Year PFCF Range
Min: 8.81   Max: 95.55
Current: 93.38

8.81
95.55
POCF 24.07
MYL's POCF is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. MYL: 24.07 )
MYL' s 10-Year POCF Range
Min: 6.09   Max: 40.56
Current: 24.07

6.09
40.56
EV-to-EBIT 23.40
MYL's EV-to-EBIT is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. MYL: 23.40 )
MYL' s 10-Year EV-to-EBIT Range
Min: -10.7   Max: 28.8
Current: 23.4

-10.7
28.8
PEG 3.17
MYL's PEG is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 3.17 )
MYL' s 10-Year PEG Range
Min: 0.37   Max: 11.64
Current: 3.17

0.37
11.64
Shiller P/E 47.42
MYL's Shiller P/E is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.82 vs. MYL: 47.42 )
MYL' s 10-Year Shiller P/E Range
Min: 10.98   Max: 701
Current: 47.42

10.98
701
Current Ratio 1.28
MYL's Current Ratio is ranked higher than
56% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. MYL: 1.28 )
MYL' s 10-Year Current Ratio Range
Min: 1.28   Max: 7.82
Current: 1.28

1.28
7.82
Quick Ratio 0.97
MYL's Quick Ratio is ranked higher than
58% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MYL: 0.97 )
MYL' s 10-Year Quick Ratio Range
Min: 0.85   Max: 6.16
Current: 0.97

0.85
6.16
Days Inventory 148.81
MYL's Days Inventory is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. MYL: 148.81 )
MYL' s 10-Year Days Inventory Range
Min: 88.95   Max: 177.15
Current: 148.81

88.95
177.15
Days Sales Outstanding 107.26
MYL's Days Sales Outstanding is ranked higher than
66% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. MYL: 107.26 )
MYL' s 10-Year Days Sales Outstanding Range
Min: 49.61   Max: 107.26
Current: 107.26

49.61
107.26

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.77
MYL's Price/DCF (Projected) is ranked higher than
83% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. MYL: 2.77 )
MYL' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 2.53
Current: 2.77

0.62
2.53
Price/Median PS Value 1.74
MYL's Price/Median PS Value is ranked higher than
63% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. MYL: 1.74 )
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.63
Current: 1.74

0.36
3.63
Price/Peter Lynch Fair Value 2.68
MYL's Price/Peter Lynch Fair Value is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 2.68 )
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.75   Max: 4.43
Current: 2.68

0.75
4.43
Earnings Yield (Greenblatt) 4.30
MYL's Earnings Yield (Greenblatt) is ranked higher than
83% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MYL: 4.30 )
MYL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 15.1
Current: 4.3

3.5
15.1
Forward Rate of Return (Yacktman) 12.11
MYL's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.09 vs. MYL: 12.11 )
MYL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.6   Max: 39.2
Current: 12.11

3.6
39.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:6MY.Germany, MYL1.Switzerland,
Mylan Inc was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted primarily in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Comments on Mylan NV Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 
John Paulson's Top Buys Feb 22 2015 
Weekly CFO Sells Highlight: Sherwin-Williams Co, Facebook Inc, Mylan Inc. Feb 09 2015 
Weekly CEO Sells Highlight: Family Dollar Stores Inc, Texas Instruments Inc, Mylan Inc, and PerkinEl Feb 09 2015 
Weekly Insider Sells Highlight: MYL, QRVO, HON, JBHT Feb 09 2015 
Zoetis in a Growing Global Animal Health Industry Dec 03 2014 
Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 


More From Other Websites
Teva Is on the Prowl and Its Stock Investors Are Taking Notice Mar 29 2015
What Drives Generic Pharmaceuticals’ Valuation? Mar 28 2015
Generic Companies Are Fighting for Market Share Mar 28 2015
Complex Generics Are Attractive Due to High Margins Mar 28 2015
Why Teva Pharmaceuticals Could Gain 25% Mar 24 2015
Teva Pharmaceuticals: Time for a Shopping Spree…and These Companies Could Be Targets Mar 17 2015
Mylan And Teva Are Catching The M&A Fever Mar 16 2015
Three trades to go before the closing bell Mar 16 2015
Theravance Biopharma's Velusetrag Enters Phase IIb Study - Analyst Blog Mar 13 2015
Mylan N.V. and Mylan Inc. Announce Successful Completion of Consent Solicitations for Mylan Inc.'s... Mar 12 2015
Mylan N.V. and Mylan Inc. Announce Successful Completion of Consent Solicitations for Mylan Inc.'s... Mar 12 2015
Mylan Breaks Out On Buyout Rumors, New Drugs Mar 12 2015
This High-Rated Drug Stock Just Neared A Buy Point Mar 12 2015
Endo Tries To Upset Valeant Bid For Salix Mar 11 2015
Sale Rumor, Drugs Launch Boost High-Rated Mylan Stock Mar 11 2015
MYLAN INC. Financials Mar 11 2015
Mylan (MYL) Stock Gains on New Drug Launches Mar 11 2015
Mylan Launches Generic Antabuse® Tablets Mar 11 2015
Mylan Launches Generic Subutex® Sublingual Tablets Mar 11 2015
Mylan Launches Generic Subutex® Sublingual Tablets Mar 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK